Cite
Katakami N, Mita T, Yoshii H, et al. Rationale, Design, and Baseline Characteristics of the Utopia Trial for Preventing Diabetic Atherosclerosis Using an SGLT2 Inhibitor: A Prospective, Randomized, Open-Label, Parallel-Group Comparative Study. Diabetes Ther. 2017;8(5):999-1013doi: 10.1007/s13300-017-0292-1.
Katakami, N., Mita, T., Yoshii, H., Shiraiwa, T., Yasuda, T., Okada, Y., Umayahara, Y., Kaneto, H., Osonoi, T., Yamamoto, T., Kuribayashi, N., Maeda, K., Yokoyama, H., Kosugi, K., Ohtoshi, K., Hayashi, I., Sumitani, S., Tsugawa, M., Ohashi, M., Taki, H., Nakamura, T., Kawashima, S., Sato, Y., Watada, H., Shimomura, I. (2017). Rationale, Design, and Baseline Characteristics of the Utopia Trial for Preventing Diabetic Atherosclerosis Using an SGLT2 Inhibitor: A Prospective, Randomized, Open-Label, Parallel-Group Comparative Study. Diabetes therapy : research, treatment and education of diabetes and related disorders, 8(5), 999-1013. https://doi.org/10.1007/s13300-017-0292-1
Katakami, Naoto, et al. "Rationale, Design, and Baseline Characteristics of the Utopia Trial for Preventing Diabetic Atherosclerosis Using an SGLT2 Inhibitor: A Prospective, Randomized, Open-Label, Parallel-Group Comparative Study." Diabetes therapy : research, treatment and education of diabetes and related disorders vol. 8,5 (2017): 999-1013. doi: https://doi.org/10.1007/s13300-017-0292-1
Katakami N, Mita T, Yoshii H, Shiraiwa T, Yasuda T, Okada Y, Umayahara Y, Kaneto H, Osonoi T, Yamamoto T, Kuribayashi N, Maeda K, Yokoyama H, Kosugi K, Ohtoshi K, Hayashi I, Sumitani S, Tsugawa M, Ohashi M, Taki H, Nakamura T, Kawashima S, Sato Y, Watada H, Shimomura I. Rationale, Design, and Baseline Characteristics of the Utopia Trial for Preventing Diabetic Atherosclerosis Using an SGLT2 Inhibitor: A Prospective, Randomized, Open-Label, Parallel-Group Comparative Study. Diabetes Ther. 2017 Oct;8(5):999-1013. doi: 10.1007/s13300-017-0292-1. Epub 2017 Sep 01. PMID: 28864997; PMCID: PMC5630549.
Copy
Download .nbib